3-(4-chlorophenyl)-N-methyl-N-(1-methylpiperidin-4-yl)propanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-chlorophenyl)-N-methyl-N-(1-methylpiperidin-4-yl)propanamide
• 化学式: C₁₆H₂₃ClN₂O
• 分子量: 294.82
• InChiKey: PPWAPQDCOKYKDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：Kumar Naresh

  公开号：US20100222393A1

  公开（公告）日：2010-09-02

  Compounds of Formula (I), wherein represents a single bond when G is —OH and double bond when G is —O; R 1 and R 2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl; R 3 is selected from the group selected from hydrogen, hydroxy, alkoxy, alkenyloxy or alkynyloxy; X is selected from oxygen, —NH, —NR (wherein R is alkyl, alkenyl, alkenyl, alkynyl or aryl), sulphur or no atom; Het is heterocyclyl or heteroaryl; n is an integer from 1 to 6; are muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and 4 i gastrointestinal systems mediated through muscarinic receptors.

  式(I)的化合物，其中当G为—OH时表示单键，当G为—O时表示双键；R1和R2分别选自氢、烷基、烯基、炔基、芳基烷基、环烷基、芳基、杂芳基、杂环烷基、杂环烷基烷基或杂芳基烷基；R3选自氢、羟基、烷氧基、烯氧基或炔氧基所选的群；X选自氧、—NH、—NR（其中R为烷基、烯基、炔基、芳基或烷基芳基）、硫或无原子；Het为杂环烷基或杂芳基；n为1至6的整数。这些化合物是肌肉性乙酰胆碱受体拮抗剂，可用于治疗通过肌肉性乙酰胆碱受体介导的呼吸系统、泌尿系统和胃肠系统的各种疾病，除其他用途外。
• SUBSTITUTED PIPERIDINES
  申请人：Dorwald Florencio Zaragoza

  公开号：US20100222386A1

  公开（公告）日：2010-09-02

  A novel class of substituted piperidines, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.

  一种新的取代哌啶类化合物、包含它们的药物组合物和在治疗和/或预防与组胺H3受体相关的疾病和紊乱方面的应用。更具体地说，这些化合物可用于治疗和/或预防与组胺H3受体相互作用有益的疾病和紊乱。
• Compositions of phosphodiesterase type IV inhibitors
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2111861A1

  公开（公告）日：2009-10-28

  Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV ("PDE-IV"), and atleast one other active ingredients selected from muscarinic receptor antagonists (MRA), β2-agonists, p38 MAP Kinase inhibitors, and corticosteroids and optionally one or more pharmaceutically acceptable excipients and/or other therapeutic agents. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.

  本文提供的药物组合物包含一种或多种IV型磷酸二酯酶抑制剂（"PDE-IV"）、至少一种选自毒蕈碱受体拮抗剂（MRA）、β2-激动剂、p38 MAP激酶抑制剂和皮质类固醇的其他活性成分，以及可选的一种或多种药学上可接受的赋形剂和/或其他治疗剂。此外，还提供了治疗自身免疫性、炎症性或过敏性疾病或紊乱的方法。
• SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR
  申请人：High Point Pharmaceuticals, LLC

  公开号：EP1434765B1

  公开（公告）日：2009-12-02
• COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS
  申请人：Ray Abhijit

  公开号：US20100004215A1

  公开（公告）日：2010-01-07

  Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV (“PDE-IV”), and at least one other active ingredient such as muscarinic receptor antagonists (MRA), β2-agonists, p38 MAP Kinase inhibitors, or corticosteroids and optionally one or more pharmaceutically acceptable excipients. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.